pubmed-article:7929531 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:7929531 | lifeskim:mentions | umls-concept:C0030551 | lld:lifeskim |
pubmed-article:7929531 | lifeskim:mentions | umls-concept:C1513095 | lld:lifeskim |
pubmed-article:7929531 | lifeskim:mentions | umls-concept:C0028458 | lld:lifeskim |
pubmed-article:7929531 | lifeskim:mentions | umls-concept:C0004565 | lld:lifeskim |
pubmed-article:7929531 | lifeskim:mentions | umls-concept:C1861502 | lld:lifeskim |
pubmed-article:7929531 | pubmed:issue | 10 | lld:pubmed |
pubmed-article:7929531 | pubmed:dateCreated | 1994-10-28 | lld:pubmed |
pubmed-article:7929531 | pubmed:abstractText | The effect of the antibiotic agent novobiocin on the sensitivity of melanoma cells to colchicine and vinblastine was examined in drug-sensitive and drug-resistant B16 melanoma cells. A cell line COL/R was selected for colchicine resistance. The COL/R cell line (resistant to 80 ng/ml colchicine) was found to possess the multidrug-resistant (MDR) phenotype. The cells were shown to be cross-resistant to vinblastine and Adriamycin and to overexpress P glycoprotein. P glycoprotein activity was assessed by using the rhodamine 123 accumulation test. Rhodamine accumulation was markedly decreased in COL/R cells as compared to the parental B16 cells. Verapamil reversed drug resistance and increased rhodamine accumulation in COL/R cells. Novobiocin in combination with colchicine or vinblastine synergistically inhibited the proliferation of parental B16 cells. In COL/R cells, novobiocin markedly decreased colchicine resistance and increased rhodamine accumulation. These data show that novobiocin increases the sensitivity of both parental and MDR melanoma cells to microtubule-disrupting cytotoxic drugs. | lld:pubmed |
pubmed-article:7929531 | pubmed:language | eng | lld:pubmed |
pubmed-article:7929531 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7929531 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:7929531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7929531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7929531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7929531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7929531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7929531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7929531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7929531 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:7929531 | pubmed:issn | 0171-5216 | lld:pubmed |
pubmed-article:7929531 | pubmed:author | pubmed-author:NovogrodskyAA | lld:pubmed |
pubmed-article:7929531 | pubmed:author | pubmed-author:SidiYY | lld:pubmed |
pubmed-article:7929531 | pubmed:author | pubmed-author:NordenbergJJ | lld:pubmed |
pubmed-article:7929531 | pubmed:author | pubmed-author:HalabeEE | lld:pubmed |
pubmed-article:7929531 | pubmed:author | pubmed-author:WassermanLL | lld:pubmed |
pubmed-article:7929531 | pubmed:author | pubmed-author:LandauOO | lld:pubmed |
pubmed-article:7929531 | pubmed:author | pubmed-author:BeeryEE | lld:pubmed |
pubmed-article:7929531 | pubmed:author | pubmed-author:KornfeldJJ | lld:pubmed |
pubmed-article:7929531 | pubmed:author | pubmed-author:ShafranMM | lld:pubmed |
pubmed-article:7929531 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:7929531 | pubmed:volume | 120 | lld:pubmed |
pubmed-article:7929531 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:7929531 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:7929531 | pubmed:pagination | 599-604 | lld:pubmed |
pubmed-article:7929531 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:7929531 | pubmed:meshHeading | pubmed-meshheading:7929531-... | lld:pubmed |
pubmed-article:7929531 | pubmed:meshHeading | pubmed-meshheading:7929531-... | lld:pubmed |
pubmed-article:7929531 | pubmed:meshHeading | pubmed-meshheading:7929531-... | lld:pubmed |
pubmed-article:7929531 | pubmed:meshHeading | pubmed-meshheading:7929531-... | lld:pubmed |
pubmed-article:7929531 | pubmed:meshHeading | pubmed-meshheading:7929531-... | lld:pubmed |
pubmed-article:7929531 | pubmed:meshHeading | pubmed-meshheading:7929531-... | lld:pubmed |
pubmed-article:7929531 | pubmed:meshHeading | pubmed-meshheading:7929531-... | lld:pubmed |
pubmed-article:7929531 | pubmed:meshHeading | pubmed-meshheading:7929531-... | lld:pubmed |
pubmed-article:7929531 | pubmed:meshHeading | pubmed-meshheading:7929531-... | lld:pubmed |
pubmed-article:7929531 | pubmed:meshHeading | pubmed-meshheading:7929531-... | lld:pubmed |
pubmed-article:7929531 | pubmed:meshHeading | pubmed-meshheading:7929531-... | lld:pubmed |
pubmed-article:7929531 | pubmed:meshHeading | pubmed-meshheading:7929531-... | lld:pubmed |
pubmed-article:7929531 | pubmed:meshHeading | pubmed-meshheading:7929531-... | lld:pubmed |
pubmed-article:7929531 | pubmed:meshHeading | pubmed-meshheading:7929531-... | lld:pubmed |
pubmed-article:7929531 | pubmed:meshHeading | pubmed-meshheading:7929531-... | lld:pubmed |
pubmed-article:7929531 | pubmed:meshHeading | pubmed-meshheading:7929531-... | lld:pubmed |
pubmed-article:7929531 | pubmed:meshHeading | pubmed-meshheading:7929531-... | lld:pubmed |
pubmed-article:7929531 | pubmed:year | 1994 | lld:pubmed |
pubmed-article:7929531 | pubmed:articleTitle | Novobiocin modulates colchicine sensitivity in parental and multidrug-resistant B16 melanoma cells. | lld:pubmed |
pubmed-article:7929531 | pubmed:affiliation | Endocrinology Laboratory, Beilinson Medical Center, Petah Tiqva, Israel. | lld:pubmed |
pubmed-article:7929531 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:7929531 | pubmed:publicationType | Comparative Study | lld:pubmed |
pubmed-article:7929531 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7929531 | lld:pubmed |